receptor blockade decreases peripheral vascular resistance and blood pressure in humans.
in coronary endothelial dysfunction and early atherosclerosis in humans.
Pressor effects of circulating endothelin
are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.
Although the endothelin
jolt didn't hurt these healthy volunteers, previous studies have shown that people with artery-clogging atherosclerosis have a higher risk of dying after a heart attack if they had endothelin
concentrations comparable to the spikes observed in the volunteers' blood.
receptor antagonists have been associated with elevations of aminotransferases, hepatotoxicity and cases of liver failure.
Tracleer (bosentan), a Dual Endothelin
Receptor Antagonist (ERA), for the Treatment of Pulmonary Arterial Hypertension (PAH) related to Connecttive Tissue Diseases: Effect on Quality of Life (QoL).
Interactions of nifedipine with the renovascular effects of endothelin
Darusentan is an oral, once-daily endothelin
receptor antagonist (ERA) being investigated in clinical trials as an add-on oral therapy for patients with resistant hypertension.
Finally, researchers are investigating combined ARB and endothelin
is produced by the endothelial cells and is essential for maintenance of normal vascular tone and function.
People with pulmonary hypertension tend to have higher-than-normal concentrations of endothelin
in their blood.
The family of potent vasoactive and mitogenic peptides, the endothelins
(ETs)  includes at least three isoforms, termed endothelin
-1, -2, and -3 (ET1, ET2, and ET3) and has been thought to play a role in a variety of cardiovascular, renal, and other disorders (1, 2).